Difference between revisions of "Mitotane"

From Dog
(Created page with "Mitotane (Lysodren; o,p'-DDD) is an antineoplastic medication used in the treatment of canine pituitary adenoma or pituitary adenocarcinoma<ref>Reine NJ (2012) Medical...")
 
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
Mitotane (Lysodren; o,p'-DDD) is an antineoplastic medication used in the treatment of canine [[pituitary adenoma]] or [[pituitary adenocarcinoma]]<ref>Reine NJ (2012) Medical management of pituitary-dependent hyperadrenocorticism: mitotane versus trilostane. ''Top Companion Anim Med'' '''27(1)''':25-30</ref>.
+
Mitotane (Lysodren; o,p'-DDD) is an antineoplastic medication used in the treatment of canine [[hyperadrenocorticism]] which occurs as a result of [[pituitary adenoma]] or [[pituitary adenocarcinoma]]<ref>Reine NJ (2012) Medical management of pituitary-dependent hyperadrenocorticism: mitotane versus trilostane. ''Top Companion Anim Med'' '''27(1)''':25-30</ref>.
  
 
Mitotane is used in adrenal cancer as adjuvant therapy, monotherapy or combined with other cytotoxic agents in advanced disease.
 
Mitotane is used in adrenal cancer as adjuvant therapy, monotherapy or combined with other cytotoxic agents in advanced disease.
Line 5: Line 5:
 
Side-effects include drug-induced [[hypoadrenocorticism]].
 
Side-effects include drug-induced [[hypoadrenocorticism]].
  
Recommended dose rate in dogs is 50 mg/kg orally once daily for five days, then once weekly maintenance therapy.
+
Recommended dose rate in dogs is 50 mg/kg orally once daily for five days, then once weekly maintenance therapy. However, as body weight increases, dose/kg or dosage/day of trilostane required to control the clinical signs of PDH decreases. Dogs weighing >30 kg might require smaller amounts of trilostane per dose or per day<ref>Feldman EC & Kass PH (2012) Trilostane dose versus body weight in the treatment of naturally occurring pituitary-dependent hyperadrenocorticism in dogs. ''J Vet Intern Med'' '''26(4)''':1078-1080</ref>.
  
 
==References==
 
==References==
 
<References/>
 
<References/>

Latest revision as of 21:03, 1 February 2013

Mitotane (Lysodren; o,p'-DDD) is an antineoplastic medication used in the treatment of canine hyperadrenocorticism which occurs as a result of pituitary adenoma or pituitary adenocarcinoma[1].

Mitotane is used in adrenal cancer as adjuvant therapy, monotherapy or combined with other cytotoxic agents in advanced disease.

Side-effects include drug-induced hypoadrenocorticism.

Recommended dose rate in dogs is 50 mg/kg orally once daily for five days, then once weekly maintenance therapy. However, as body weight increases, dose/kg or dosage/day of trilostane required to control the clinical signs of PDH decreases. Dogs weighing >30 kg might require smaller amounts of trilostane per dose or per day[2].

References

  1. Reine NJ (2012) Medical management of pituitary-dependent hyperadrenocorticism: mitotane versus trilostane. Top Companion Anim Med 27(1):25-30
  2. Feldman EC & Kass PH (2012) Trilostane dose versus body weight in the treatment of naturally occurring pituitary-dependent hyperadrenocorticism in dogs. J Vet Intern Med 26(4):1078-1080